Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in majic: an investigator lead randomized trial

Eitemau Tebyg

• Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial
  gan: Harrison, C, et al.
  Cyhoeddwyd: (2017)
• Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared Ruxolitinib to best available therapy in essential thrombocythemia
  gan: Harrison, C, et al.
  Cyhoeddwyd: (2016)
• Longitudinal mutational analysis in hydroxycarbamide-resistant/intolerant essential thrombocythemia treated on the majic-ET study
  gan: O'Sullivan, J, et al.
  Cyhoeddwyd: (2018)
• The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib
  gan: O'Sullivan, JM, et al.
  Cyhoeddwyd: (2019)
• Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial
  gan: Harrison, CN, et al.
  Cyhoeddwyd: (2023)